Study reveals shorter scans for prostate cancer could improve diagnosis
The most common form of cancer in men is responsible for 12,000 deaths every year in the UK
Read More
Tag: PRIME
EU regulators to review Evrysdi for SMA
The decision triggers a £15m milestone payment from Roche to PTC Therapeutics
Read More
PRIME status for Adaptimmune’s synovial sarcoma drug
The drug has the potential to address an unmet need
Read More
EMA PRIME status granted to Janssen’s inherited retinal disease gene therapy
The designation makes the drug the only XLRP treatment in development to be awarded PRIME designation.
Read More
EMA grants PRIME designation to Janssen’s investigational CAR-T therapy
Based on a study that found 88% overall response rate in advanced relapsed or refractory multiple myeloma.
Read More
AZ’ RSV drug bags EMA PRIME, FDA Breakthrough statuses
AstraZeneca’s MEDI8897 has been granted access to both the European Medicines Agency (EMA) PRIME (PRIority MEdicines) scheme, and the US Food and Drug Administration’s (FDA) Breakthrough Therapy Designation (BTD).
Read More
PRIME status for Orchard’s gene therapy
The European Medicines Agency has granted Orchard Therapeutics’ experimental gene therapy OTL-300 PRIME designation as a potential treatment for the most severe form of beta-thalassemia.
Read More
EU PRIME status for Mereo’s brittle bone drug
London, UK-based Mereo BioPharma’s experimental drug targeting brittle bone disease has been designated PRIME status by the European Medicines Agency (EMA).
Read More
PRIME status for Ignyta’s entrectinib
European regulators have awarded Ignyta’s cancer drug entrectinib Priority Medicines (PRIME) designation, potentially placing the treatment on a faster path to approval.
Read More
Kite first to submit CAR-T therapy in Europe
Kite Pharma has submitted the first CAR-T cell therapy in Europe, seeking permission to market its axicabtagene ciloleucel (axi-cel) to treat patients with three subtypes of aggressive non-Hodgkin lymphoma (NHL).
Read More
Experimental sickle cell disease drug gets PRIME status
Global Blood Therapeutics’ GBT440 has become the first potential treatment for sickle cell disease to be accepted onto the European Medicines Agency’s regulatory support programme PRIME.
Read More
UniQure’s haemophilia B therapy picks up PRIME status
uniQure’s investigational gene therapy for patients with the blood clotting disorder haemophilia B has been awarded PRIME status by European regulators, potentially placing the treatment on a faster path to approval.
Read More
- NHS addresses shortage of ethnic organ and blood donors with £600,000 funding
- NIHR awards HealthTech Research Centre Network £5m to advance health innovations
- KCL researchers identify key features of autoimmune diseases present in the gut
- Vicore and Endeavor’s therapies show promise in treating IPF
- Liverpool and McMaster University announce £300,000 strategic research partnership
